Oncology & Cancer

Vigil immunotherapy tolerated well for recurrent ovarian CA Tx

(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to ...

Oncology & Cancer

Study tracks evolutionary transition to destructive cancer

Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Oncology & Cancer

Some leukaemia patients may be missing out on new treatments

Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from some of these new drugs, according to new research by Queen Mary University of London.

page 2 from 15